Posts By :

admin

Diffusion Pharmaceuticals Reports 2021 Financial Results and Provides Business Update
Diffusion Pharmaceuticals Reports 2021 Financial Results and Provides Business Update 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., March 21, 2022 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Expands its Scientific Advisory Board with the Addition of Leading Radiation and Medical Oncology Experts
Diffusion Pharmaceuticals Expands its Scientific Advisory Board with the Addition of Leading Radiation and Medical Oncology Experts 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., Feb. 24, 2022 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals to Present at H.C. Wainwright BioConnect, Participate in Biotech Showcase and Bio Partnering at JPM during “J.P. Morgan Week 2022”
Diffusion Pharmaceuticals to Present at H.C. Wainwright BioConnect, Participate in Biotech Showcase and Bio Partnering at JPM during “J.P. Morgan Week 2022” 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., Dec. 20, 2021 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Doses First Patients in ILD-DLCO Trial
Diffusion Pharmaceuticals Doses First Patients in ILD-DLCO Trial 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., Dec. 16, 2021 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Announces Issuance of U.S. Patent 11,185,523
Diffusion Pharmaceuticals Announces Issuance of U.S. Patent 11,185,523 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., Dec. 01, 2021 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Doses First Participants in Altitude Trial
Diffusion Pharmaceuticals Doses First Participants in Altitude Trial 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., Nov. 22, 2021 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update
Diffusion Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., Nov. 10, 2021 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals to Participate in the Alliance Global Partners Biotech & Specialty Pharma Conference
Diffusion Pharmaceuticals to Participate in the Alliance Global Partners Biotech & Specialty Pharma Conference 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., Oct. 28, 2021 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc.

Episode 2: Exploring TSC’s Impact on Tissue-Level Changes in Oxygen
Episode 2: Exploring TSC’s Impact on Tissue-Level Changes in Oxygen 150 150 Diffusion Pharmaceuticals Inc.

Dr. Chris Galloway, Chief Medical Officer of Diffusion, explains the TCOM Trial design, top-line results, and the relevancy of this first of three Oxygenation Trials that together will inform late-phase programs and clinical indications for lead drug candidate TSC.

Diffusion Pharmaceuticals Issues Letter to Shareholders
Diffusion Pharmaceuticals Issues Letter to Shareholders 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., Sept. 09, 2021 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc.

Back to top